Sustained-Release Bupropion for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Publisher Website
Google Scholar
Abstract
The authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs). Thirty adults who had received SSRIs for at least 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greater than 19 out of a possible 30 on the Arizona Sexual Experience Scale were randomly assigned to receive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks. There were no significant differences between the sustained-release bupropion and placebo groups as measured by change in Arizona Sexual Experiences Scale or Hamilton Depression Rating Scale scores or side effects. Future studies should compare higher doses of bupropion for treating sexual dysfunction and should include a greater number of subjects.